Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) rose nearly 18% in the afternoon ASC47 preclinical studies suggest it has the potential to lose fat, gain muscle, and lose weight

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose nearly 18% in the afternoon. As of press release, it had risen 16.95% to HK$11.52, with a turnover of HK$114 million.

According to the news, Goli Pharmaceuticals announced that a randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) to evaluate the safety, tolerability, and initial efficacy of ultra-long-lasting subcutaneous ASC47 administration in obese subjects without type 2 diabetes (ASC47-103 study,) has recently completed administration of all 28 subjects. The enrollment of 28 subjects was completed quickly within two months.

CITIC Construction Investment points out that the ASC47 preclinical study has the effect of reducing fat, muscle gain, and weight loss, and has full potential. The company's ASC47 preclinical study showed that when treated with simeglutide to mice, the combined group showed a higher weight loss trend compared to the smeglutide group. At the same time, the product combined with simeglutide also showed a trend of more fat loss and muscle retention. Overall, ASC47 showed initial ability to lose fat, gain muscle, and lose weight in pre-clinical animal models, and the results of subsequent human studies can be expected.